[go: up one dir, main page]

MX2010005113A - Incremento de la respuesta inmunitaria y reconocimiento del objetivo por antigenos y/o enlace a farmaco. - Google Patents

Incremento de la respuesta inmunitaria y reconocimiento del objetivo por antigenos y/o enlace a farmaco.

Info

Publication number
MX2010005113A
MX2010005113A MX2010005113A MX2010005113A MX2010005113A MX 2010005113 A MX2010005113 A MX 2010005113A MX 2010005113 A MX2010005113 A MX 2010005113A MX 2010005113 A MX2010005113 A MX 2010005113A MX 2010005113 A MX2010005113 A MX 2010005113A
Authority
MX
Mexico
Prior art keywords
immune response
antigens
targeting
increase
compounds
Prior art date
Application number
MX2010005113A
Other languages
English (en)
Inventor
Vincent Serra
Original Assignee
Wyttycell
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyttycell filed Critical Wyttycell
Publication of MX2010005113A publication Critical patent/MX2010005113A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C07H15/06—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical being a hydroxyalkyl group esterified by a fatty acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere los compuestos que consisten de glucolípidos covalentemente enlazados a un antígeno o un fármaco vía un enlazador. Los compuestos son capaces de inducir una respuesta inmunitaria más fuerte que una composición que comprende glucolípidos separados y antígeno. Los compuestos son también capaces de dirigir el fármaco a las células restringidas a CD1d.
MX2010005113A 2007-11-07 2008-11-07 Incremento de la respuesta inmunitaria y reconocimiento del objetivo por antigenos y/o enlace a farmaco. MX2010005113A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US99622607P 2007-11-07 2007-11-07
EP07291336A EP2058011A1 (en) 2007-11-07 2007-11-07 Nkt cell activating gycolipids covalently bound antigens and/or drug
PCT/EP2008/065179 WO2009060086A2 (en) 2007-11-07 2008-11-07 Increase of immune response and targeting by antigens and/or drug linkage

Publications (1)

Publication Number Publication Date
MX2010005113A true MX2010005113A (es) 2010-10-07

Family

ID=39110389

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010005113A MX2010005113A (es) 2007-11-07 2008-11-07 Incremento de la respuesta inmunitaria y reconocimiento del objetivo por antigenos y/o enlace a farmaco.

Country Status (15)

Country Link
US (1) US8642565B2 (es)
EP (2) EP2058011A1 (es)
JP (1) JP5404639B2 (es)
CN (1) CN101918033B (es)
AU (1) AU2008324118B2 (es)
BR (1) BRPI0820258B8 (es)
CA (1) CA2705067C (es)
DK (1) DK2231196T3 (es)
ES (1) ES2584928T3 (es)
IL (1) IL205583A (es)
MX (1) MX2010005113A (es)
PT (1) PT2231196T (es)
RU (1) RU2548685C2 (es)
WO (1) WO2009060086A2 (es)
ZA (1) ZA201003286B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8916164B2 (en) * 2007-08-29 2014-12-23 Abivax Methods of enhancing adjuvaticity of vaccine compositions
EP2231145B1 (en) 2007-12-05 2014-09-17 Wittycell Use of glycosylceramides for enhancing the immune response to antigens
BR112014023193A2 (pt) * 2012-03-19 2017-08-01 Max Planck Gesellschaft composto da fórmula geral (i): a[l-ch-ca]p e formulação de vacina
CN104736550B (zh) * 2012-07-26 2017-12-29 维多利亚联结有限公司 有机化合物
AU2013356790B2 (en) 2012-12-06 2018-03-08 Victoria Link Limited Conjugate compounds
US10046046B2 (en) * 2014-06-05 2018-08-14 Victoria Link Limited Amino sphingoglycolipid analogues
EP3925963A1 (en) * 2020-06-18 2021-12-22 Helmholtz-Zentrum für Infektionsforschung GmbH Phytosphingosine derivatives as adjuvants in immune stimulation
EP4213876A4 (en) * 2020-09-17 2024-09-25 Board of Regents, The University of Texas System PHARMACEUTICAL COMPOSITIONS OF NICLOSAMIDE AND A PROTEIN
IL305579A (en) 2021-03-01 2023-10-01 Deciduous Therapeutics Inc Compounds for activating invariant natural killer T cells and methods for use in eliminating inflammatory senescent cells

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1592453A (en) 1976-05-14 1981-07-08 Smith Kline French Lab Aminoalkyl esters of carbarimidothioic acid and compositions having immunosuppressant activity
US5242800A (en) 1990-01-30 1993-09-07 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Receptor for pathogenic fungi
US5936076A (en) 1991-08-29 1999-08-10 Kirin Beer Kabushiki Kaisha αgalactosylceramide derivatives
TW261533B (es) 1992-07-16 1995-11-01 Kirin Brewery
WO1994009020A1 (fr) 1992-10-22 1994-04-28 Kirin Beer Kabushiki Kaisha Nouveau shingoglycolipide et son utilisation
DE69416306T2 (de) 1993-04-15 1999-06-17 Kirin Beer K.K., Tokio/Tokyo Sphingoglycolipid und verwendung davon
CA2162478A1 (en) 1993-05-14 1994-11-24 Shawn A. Defrees Sialyl lex analogues as inhibitors of cellular adhesion
US6054433A (en) 1994-11-03 2000-04-25 The Regents Of The University Of California Methods and compositions for stimulating tissue growth and epithelial moisturization
US5785975A (en) 1995-06-26 1998-07-28 Research Triangle Pharmaceuticals Adjuvant compositions and vaccine formulations comprising same
EP0821068A3 (en) 1996-03-29 1999-06-02 Rohm And Haas Company Novel sphingolipids and a process thereto
US6417167B1 (en) 1997-02-05 2002-07-09 Kirin Beer Kabushiki Kaisha Lyophilized compositions containing shingoglycolipid and process for preparing them
ES2221147T3 (es) 1997-02-05 2004-12-16 Kirin Beer Kabushiki Kaisha Composiciones liofilizadas conteniendo glicoesfingolipidos.
CA2286482C (en) 1997-04-10 2008-08-05 Kirin Beer Kabushiki Kaisha Nkt cell-activating agents containing .alpha.-glycosylceramides
EP1049477A1 (en) 1997-12-30 2000-11-08 A+ Science Invest AB Galactosylceramide, glucosylceramide, lactosylceramide, and specific catchers therefor for use in the prophylaxis or therapy of prediabetes, diabetes and/or associated complications
WO1999041266A1 (en) 1998-02-12 1999-08-19 Emory University Sphingolipid derivatives and their methods of use
US20030157113A1 (en) 1999-12-28 2003-08-21 Terman David S. Compositions and methods for treatment of neoplastic disease
US20030153514A1 (en) 2000-04-28 2003-08-14 Akikuni Yagita Remedies for cancer
JP4410913B2 (ja) 2000-06-12 2010-02-10 壽製薬株式会社 新規糖脂質誘導体の製造方法
US20020115624A1 (en) 2000-06-22 2002-08-22 Behar Samuel M. Alpha gylcosylceramides for treating bacterial and fungal infections
WO2002018539A2 (en) 2000-08-25 2002-03-07 Lysometrix Corporation Method for assaying the activity of lysosomal enzymes
CA2453880A1 (en) 2001-07-25 2003-02-06 New York University Use of glycosylceramides as adjuvants for vaccines against infections and cancer
KR100549866B1 (ko) 2001-08-22 2006-02-08 고려대학교 산학협력단 암치료 및 예방 제제
US7459461B2 (en) * 2001-10-19 2008-12-02 Ortho-Mcneil Pharmaceutical, Inc. Phosphonic acid compounds as inhibitors of serine proteases
US20040266726A1 (en) 2001-11-06 2004-12-30 Akikuni Yagita Anticancer compositions
US7273853B2 (en) 2002-05-13 2007-09-25 Enanta Pharmaceuticals, Inc. 6-11 bicyclic ketolide derivatives
AU2003251518B2 (en) 2002-06-13 2009-07-02 New York University Synthetic C-glycolipid and its use for treating cancer infectious diseases and autoimmune diseases
US7645873B2 (en) 2003-03-20 2010-01-12 The Scripps Research Institute 6″-amino-6″-deoxygalactosylceramides
AU2003225891A1 (en) 2003-03-20 2004-11-19 Brigham Young University 6"-amino-6"-deoxygalactosylceramides
GB0314682D0 (en) 2003-06-24 2003-07-30 Isis Innovation Materials and methods relating to the modulation of T cell response to soluble antigen
US7771726B2 (en) 2003-10-08 2010-08-10 New York University Use of synthetic glycolipids as universal adjuvants for vaccines against cancer and infectious diseases
EP1732384A4 (en) 2004-03-31 2008-04-23 Univ New York State Res Found NOVEL SYNTHETIC C-GLYCOLIPIDES, THEIR SYNTHESIS AND USE FOR THE TREATMENT OF INFECTIONS, CANCER AND AUTOIMMUNE DISEASES
WO2006026389A2 (en) 2004-08-27 2006-03-09 Albert Einstein College Of Medicine Of Yeshiva University Ceramide derivatives as modulators of immunity and autoimmunity
DE602005020643D1 (de) 2004-09-03 2010-05-27 Univ Chicago Verfahren zur aktivierung von nkt-zellen
EP1833489A4 (en) 2004-12-28 2011-08-03 Univ Rockefeller GLYCOLIPIDES AND ANALOGUE THEREOF AS ANTIGENS FOR NK-T CELLS
PL1848813T3 (pl) 2005-01-28 2013-09-30 Univ Brigham Young Aktywacja glikolipidem bakteryjnym komórek NKT podlegających restrykcji CD1d
KR100764678B1 (ko) 2005-07-13 2007-10-09 재단법인서울대학교산학협력재단 알파-갈락토실세라마이드를 아쥬반트로 포함하는 비강투여용 백신 조성물
WO2007050668A1 (en) 2005-10-25 2007-05-03 Ludwig Institute For Cancer Research Analogs of alpha galactosylceramide and uses thereof
WO2007051004A2 (en) * 2005-10-28 2007-05-03 The Brigham And Women's Hospital, Inc. Conjugate vaccines for non-proteinaceous antigens
EP2056842B1 (en) * 2006-04-07 2012-10-17 The Scripps Research Institute Modified-galactosyl ceramide for the treatment of cancerous diseases
EP2040541B1 (en) 2006-06-30 2016-03-23 The Scripps Research Institute Adjuvants and methods of use
EP1938836A1 (en) 2006-12-28 2008-07-02 Universite Rene Descartes (Paris V) Compositions comprising a B subunit of shiga toxin and a means stimulating NKT cells
EP2231145B1 (en) * 2007-12-05 2014-09-17 Wittycell Use of glycosylceramides for enhancing the immune response to antigens

Also Published As

Publication number Publication date
JP2011503034A (ja) 2011-01-27
CN101918033A (zh) 2010-12-15
ES2584928T3 (es) 2016-09-30
WO2009060086A2 (en) 2009-05-14
EP2058011A1 (en) 2009-05-13
EP2231196A2 (en) 2010-09-29
IL205583A (en) 2014-05-28
EP2231196B1 (en) 2016-05-25
BRPI0820258B1 (pt) 2020-08-18
AU2008324118B2 (en) 2013-05-16
AU2008324118A1 (en) 2009-05-14
RU2010122946A (ru) 2011-12-20
DK2231196T3 (en) 2016-08-22
WO2009060086A3 (en) 2009-12-10
US20100330111A1 (en) 2010-12-30
CA2705067A1 (en) 2009-05-14
CA2705067C (en) 2016-08-16
ZA201003286B (en) 2011-03-30
RU2548685C2 (ru) 2015-04-20
JP5404639B2 (ja) 2014-02-05
IL205583A0 (en) 2010-11-30
PT2231196T (pt) 2016-08-23
US8642565B2 (en) 2014-02-04
BRPI0820258A2 (pt) 2017-04-04
CN101918033B (zh) 2012-12-05
BRPI0820258B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
MX2010005113A (es) Incremento de la respuesta inmunitaria y reconocimiento del objetivo por antigenos y/o enlace a farmaco.
WO2009100194A3 (en) Camptothecin-binding moiety conjugates
MX350200B (es) Anticuerpos humanos y conjugados de anticuerpo-farmaco contra cd74.
WO2009061996A3 (en) Antibodies that bind human dendritic and epithelial cell 205 (dec-205)
WO2007112193A3 (en) Camptothecin-binding moiety conjugates
HK1200464A1 (en) Immunobinders directed against tnf
PH12012501991A1 (en) Tnf-alpha binding proteins
MX338754B (es) Anticuerpos humanos contra el factor tisular.
WO2007089871A8 (en) Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders
TR201000668T1 (tr) Neoplasti̇k veya enfeksi̇yoz bozukluklara yöneli̇k i̇mmunoprofi̇laksi̇ veya i̇mmünoterapi̇ i̇çi̇n poli̇pepti̇d-nüklei̇k asi̇t konjugati
WO2012112696A8 (en) Therapeutic compositions and methods for antibody and fc-containing targeting molecule-based targeted delivery of bioactive molecules by bacterial minicells
MX2013003452A (es) Conjugados de amatoxina con enlazantes mejorados.
WO2009083009A3 (en) Monoclonal antibodies against cd32b
MY158560A (en) Composition comprising antiboby that binds to domain ii of her2 and acidic variants thereof
EP4483963A3 (en) Monoclonal antibodies against c-met
WO2011032161A3 (en) Vaccines directed to langerhans cells
NZ592432A (en) Antibodies that specifically block the biological activity of a tumor antigen Kidney associated antigen 1 (KAAG1)
WO2011130434A3 (en) Antibodies that bind human cd27 and uses thereof
EP4434550A3 (en) Human antibody drug conjugates against tissue culture
IN2015DN00694A (es)
IN2012DN03025A (es)
WO2010107487A3 (en) Lipid-drug conjugates for drug delivery
UA95959C2 (en) Leptomycin derivatives
EP3450459A3 (en) Anti-cdh3 antibodies and uses thereof
EP2952210A3 (en) Compositions comprising saccharide binding moieties and methods for targeted therapy

Legal Events

Date Code Title Description
FG Grant or registration
PD Change of proprietorship

Owner name: ABIVAX